RT Journal Article
T1 Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer.
A1 Navarro-Ocon, Alba
A1 Blaya-Canovas, Jose L
A1 Lopez-Tejada, Araceli
A1 Blancas, Isabel
A1 Sanchez-Martin, Rosario M
A1 Garrido, María J
A1 Griñan-Lison, Carmen
A1 Calahorra, Jesus
A1 Cara, Francisca E
A1 Ruiz-Cabello, Francisco
A1 Marchal, Juan A
A1 Aptsiauri, Natalia
A1 Granados-Principal, Sergio
K1 breast cancer
K1 cancer immunotherapy
K1 cancer treatment
K1 immune escape
K1 nanomedicine
AB Breast cancer is the most common type of malignancy and leading cause of cancer death among women worldwide. Despite the current revolutionary advances in the field of cancer immunotherapy, clinical response in breast cancer is frequently below expectations, in part due to various mechanisms of cancer immune escape that produce tumor variants that are resistant to treatment. Thus, a further understanding of the molecular events underlying immune evasion in breast cancer may guarantee a significant improvement in the clinical success of immunotherapy. Furthermore, nanomedicine provides a promising opportunity to enhance the efficacy of cancer immunotherapy by improving the delivery, retention and release of immunostimulatory agents in targeted cells and tumor tissues. Hence, it can be used to overcome tumor immune escape and increase tumor rejection in numerous malignancies, including breast cancer. In this review, we summarize the current status and emerging trends in nanomedicine-based strategies targeting cancer immune evasion and modulating the immunosuppressive tumor microenvironment, including the inhibition of immunosuppressive cells in the tumor area, the activation of dendritic cells and the stimulation of the specific antitumor T-cell response.
PB MDPI AG
SN 1999-4923
YR 2022
FD 2022-02-23
LK http://hdl.handle.net/10668/21545
UL http://hdl.handle.net/10668/21545
LA en
NO Navarro-Ocón A, Blaya-Cánovas JL, López-Tejada A, Blancas I, Sánchez-Martín RM, Garrido MJ, et al. Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer. Pharmaceutics. 2022 Feb 25;14(3):505.
NO S.G.-P. was supported by Instituto de Salud Carlos III (CP14/00197, CP19/00029) and theEuropean Regional Development Fund (European Union). This work was funded by Instituto deSalud Carlos III (PI15/00336, PI19/01533), Ministerio de Ciencia e Innovación (PID2020-115087GB100, RTI2018.101309B-C22) and Junta de Andalucía (B-CTS-410-UGR-20). A.N.-O. was supported bySistema Nacional de Garantía Juvenil (Fondo Social Europeo). J.L.B.-C. was supported by FundaciónCientífica Asociación Española Contra el Cáncer, Junta Provincial de Jaén (AECC) (PRDJA19001BLAY),and A.L.T. was funded by Ministerio de Ciencia, Innovación y Universidades (FPU19/04450). C.G.-L.was funded by Junta de Andalucía, Consejería de Salud y Familias (RH-0139-2020), J.C. was fundedby Junta de Andalucía, Consejería de Transformación Económica, Industria, Conocimiento y Universidades (DOC_01686).
DS RISalud
RD Apr 18, 2025